Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02463994 · ClinicalTrials.gov registry record · Early Phase 1
A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC
A Early Phase 1 study of Non-Small Cell Lung Cancer, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
- 2
- Study locations
NCT02463994 is a Early Phase 1 study of Non-Small Cell Lung Cancer that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 12 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT02463994, a Early Phase 1 study of Non-Small Cell Lung Cancer, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to find out whether a brief course of radiation therapy given to one area affected by the cancer will improve the chances of responding to immuno-therapy in the form of a medicine called MPDL3280A, an antibody against PD-L1. PD-L1 is expressed on lung cancers and is known to block the effects of the body's immune system in attacking the cancer. Blocking this PD-L1 has been shown to improve the body's immune cells to attack and kill the cancer cells in non-small cell lung cancer. The goal of this study is to see if prior treatment with radiation will allow improved recognition of the cancer by the body's immune cells in the presence of MPDL3280A.
Conditions Studied
Interventions
- DRUG MPDL3280A
- RADIATION Hypofractionated Radiotherapy
Study Locations (2)
Michigan
- The University of Michigan Comprehensive Cancer Center - Ann Arbor
Washington
- University of Washington, Seattle - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-10 |
| Est. Completion | 2018-11-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02463994
The ClinicalTrials.gov registry entry for NCT02463994 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (98% lower). The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which MPDL3280A is the first listed.
NCT02463994 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Michigan, Washington.
Frequently Asked Questions
What is clinical trial NCT02463994 about?
NCT02463994 is a clinical study titled "A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC". The purpose of this study is to find out whether a brief course of radiation therapy given to one area affected by the cancer will improve the chances of responding to immuno-therapy in the form of a medicine called MPDL3280A, an antibody against PD-L1. PD-L1 is expressed on lung cancers and is know...
What is the current status of trial NCT02463994?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2015-10. Estimated completion is 2018-11-07.
What conditions does trial NCT02463994 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT02463994?
The interventions under investigation include: MPDL3280A (DRUG), Hypofractionated Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT02463994?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02463994 being conducted?
This trial has 2 study locations across Michigan, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
RECRUITING · Early Phase 1
-
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
RECRUITING · Early Phase 1
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.